Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer

Dysregulated HGF/c-Met pathway has been implicated in multiple human cancers and has become an attractive target for cancer intervention. Herein, we report the discovery of N-(3-fluoro-4-((2-(3-hydroxyazetidine-1-carboxamido)pyridin-4-yl)oxy)phenyl)-1-(4-fluorophenyl)-4-methyl-6-oxo-1,6-dihydropyrid...

Descrición completa

Detalles Bibliográficos

Principais autores:	Lijie Sima, Zhongyuan Wang, Ling Yu, Youli Hou, Dongsheng Zhao, Bilan Luo, Weike Liao, Xinfu Liu
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2024-12-01
Series:	Journal of Enzyme Inhibition and Medicinal Chemistry
Assuntos:	c-Met LAH-1 antitumor activity NSCLC
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/14756366.2023.2286435
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!